Loading…
← CockpitCompetitor Analysis › 300003.SZ Lepu Medical Technology (Beijing) Co., Ltd. Class AOpen in the cockpit ↗

Lepu Medical Technology (Beijing) Co., Ltd. Class A300003.SZCompetitor analysis, valuation and peers

China · CNY·Health Care›Medical Specialties

Major Chinese cardiovascular device maker selling coronary stents, heart valves, pacemakers and diagnostic reagents.

≈ A Chinese Abbott Cardiovascular/Medtronic hybridMomentum strong 80
Mkt cap
$3.20B
US dollars, full cap
Free float
72%
of shares outstanding
$/day
$41.5M
20-day average traded
Fwd P/E
24.4×
forward earnings
ROIC−WACC
-2.1 pp
WACC 6.7%
Hurdle
+13 pp
Req g minus delivered
Next earnings
161 days
28 Apr 2027
Close · CNYCN¥11.88
1D-1.6%
1W-2.9%
1M+2.5%
3M-9.7%
6M-12.8%
YTD-24.9%
1Y-31.3%
ATR %2.8%
52w lowhigh45.0% off high

What Lepu Medical Technology (Beijing) does

Major Chinese cardiovascular device maker selling coronary stents, heart valves, pacemakers and diagnostic reagents.

National bulk purchasing of coronary stents, started in 2020, forced prices sharply lower, so the company has been leaning more on heart valves, pacemakers and other products. It sells through hospitals via distributors, with hospital tenders deciding volume.

In one line: A Chinese Abbott Cardiovascular/Medtronic hybrid.

Products and services

  • Coronary stents
  • Heart valves (structural heart)
  • Pacemakers/CRM devices
  • In-vitro diagnostic reagents

Customers

  • Cardiologists/hospitals

Where it sits in the supply chain

  • Health Care
  • Medical devices
  • Cardiovascular & structural heart…

What could go right

  • China cardiovascular procedure-volume growth
  • Overseas market expansion

What could go wrong

  • Volume-based procurement price cuts

Moat: narrow (IP / patents, regulatory licence, installed base). Device approvals, physician training and installed base favor an established incumbent.

Headquarters: Beijing, China · Founded: 1999 · Employees: 8,689

Named competitors

Lepu Medical Technology (Beijing) at a glance

Size Lepu Medical Technology (Beijing) (300003.SZ) is a China Health Care company (Medical Specialties) with a market value of $3.20B, the 755th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥11.88 on 18 Nov 2026.

Performance Over six months the shares fell 12.8%, against +3.2% for the median peer and -20.0% for the China market (cap-weighted) — 7th lowest of 21 in its peer set.

Growth Revenue fell 1.4% over the last twelve months (peer median +7.2%); the operating margin is 12.6% (peer median 7.8%).

Valuation It trades at 24.4× forward earnings against a peer median of 25.7× (8th cheapest of 18).

Price implies For today's price to make sense, revenue must grow about 9% a year for seven years (Req g). Recent delivered growth is -4%, so the hurdle is +13 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 2.1 points below its cost of capital (6.7% WACC).

Next results Next results expected around 28 Apr 2027 (exchange calendar; dates can move).

Relative performance

9010011021 May 202621 Aug 202618 Nov 2026Peer median 104300003.SZ 90
Six months, rebased to 100: Lepu Medical Technology (Beijing) against the median of its 20 peers (local-currency closes).

Lepu Medical Technology (Beijing) financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥6.17BCN¥6.43BCN¥6.05BCN¥7.92BCN¥10.5B
Revenue growth—+6%-24%-25%—
Gross profitCN¥4.04BCN¥3.75BCN¥3.31BCN¥4.74BCN¥6.24B
EBITDAn/aCN¥1.95BCN¥1.07BCN¥2.17BCN¥3.27B
Net incomeCN¥658MCN¥962MCN¥247MCN¥1.26BCN¥2.20B
Free cash flowCN¥716MCN¥1.06BCN¥156MCN¥319MCN¥1.91B
Capital expenditureCN¥882MCN¥643MCN¥659MCN¥845MCN¥905M
Total debtCN¥6.37BCN¥6.52BCN¥5.90BCN¥5.12BCN¥4.57B

Quarterly statements and history in the cockpit →

Lepu Medical Technology (Beijing) competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-25%0%+25%+50%+75%-20%0%+20%IRTCAFX603301688301688114TMDX603658PLSEAXGNAMBU-B4203TECNATRC603014COTN1SXPCELCNVSTOBCK002432300003.SZ6-month return →1-month return →
Up and to the right = strong over both horizons. Lepu Medical Technology (Beijing) is the large dot.

Fundamentals: revenue growth against valuation

-25%0%+25%+50%0×100×200×IRTCAFX603301688301TMDX603658AXGNAMBU-B4203TECNATRCCOTN002432300003.SZRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Lepu Medical Technology (Beijing) is the large dot.

Capital: growth delivered against growth the price implies

0%+25%+50%+75%0%50%IRTCAFX603301688114TMDX603658AXGNTECN6030141SXP002432300003.SZGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Lepu Medical Technology (Beijing) is the large dot.

Lepu Medical Technology (Beijing) competitors and peer comparison

Head to head with its named competitors (300003.SZ vs ABT vs MDT vs 0853.HK)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Lepu Medical Technology (Beijing) 300003.SZ$3.20B-13%-1%13%24.4×8.7%
Abbott Laboratories ABT$181B+18%+10%14%17.9×16.5%
Medtronic MDT$129B+30%+10%20%16.8×9.1%
MicroPort Scientific 0853.HKn/a-45%n/an/an/an/a
Boston Scientific BSX$63.3B-23%+9%21%14.1×5.8%

How Lepu Medical Technology (Beijing) compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Lepu Medical Technology (Beijing) against its 20 peers (data as of 18 Nov 2026)
Measure300003.SZPeer medianRank in peer set
1-month return+2.5%-4.1%9th highest of 21
6-month return-12.8%+3.2%7th lowest of 21
Distance from 52-week high-45.0%-27.7%5th lowest of 21
Revenue growth (TTM)-1.4%+7.2%4th lowest of 20
Operating margin12.6%7.8%7th highest of 19
Forward P/E24.4×25.7×8th cheapest of 18
Growth the price implies (Req g, 7 yrs)8.7%12.6%7th least demanding of 17
Growth delivered (Del g)-4.2%+8.5%3rd lowest of 17
Hurdle (Req g minus delivered)+12.9 pp+1.2 pp7th most demanding of 17
ROIC minus cost of capital-2.1 pp-1.1 pp8th lowest of 18

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Lepu Medical Technology (Beijing) 300003.SZChina$3.20B-13%-1%13%24.4×8.7%-4.2%
iRhythm IRTCUnited States$3.19B-19%+22%5%99.8×46.9%+23.0%
Carl Zeiss Meditec AFX.DEGermany$3.17B+22%0%8%24.4×12.5%+10.8%
Zhende Medical 603301.SSChina$3.26B-10%+8%7%42.5×22.9%-16.1%
iRay Technology 688301.SSChina$3.31B-30%+58%24%25.7×n/an/a
MGI Tech 688114.SSChina$3.06B-4%+2%-7%n/a43.7%-0.1%
TransMedics TMDXUnited States$3.35B+42%+28%12%43.4×38.4%+88.2%
Autobio Diagnostics 603658.SSChina$3.36B+16%+3%25%20.3×-0.4%+7.2%
Pulse Biosciences PLSEUnited States$3.37B+76%+1,637%-5,821%n/an/an/a
Axogen AXGNUnited States$3.40B+33%+24%-5%87.3×52.6%+14.9%
Ambu A/S AMBU-B.CODenmark$3.47B+31%+7%13%28.8×10.0%+10.0%
Sumitomo Bakelite 4203.TJapan$3.50B+7%+15%13%15.9×8.6%+8.9%
Tecan TECN.SWSwitzerland$3.60B+59%-4%1%35.5×45.4%+3.8%
AtriCure ATRCUnited States$2.82B+91%+14%3%212.4×54.2%+20.9%
Shandong Weigao Blood Purification Products 603014.SSChina$3.63B-1%+4%n/a20.4×-1.2%+8.1%
COMET COTN.SWSwitzerland$2.78B-15%-3%6%32.8×n/an/a
SCHOTT Pharma AG & Co. KGaA 1SXP.DEGermany$3.73B+32%+4%15%23.0×12.7%+11.0%
Celcuity CELCUnited States$2.73B-60%n/an/an/an/an/a
Envista NVSTUnited States$3.81B0%+10%12%14.7×4.8%+7.1%
Ottobock SE & Co. KGaA OBCK.DEGermany$2.65B-30%+5%17%12.3×-1.2%+8.0%
Andon Health 002432.SZChina$3.86B-24%-30%-26%16.1×-6.6%-7.4%

Questions

Who are Lepu Medical Technology (Beijing)'s main competitors?
Named competitors: Abbott Laboratories (ABT), Medtronic (MDT), MicroPort Scientific (0853.HK), Boston Scientific (BSX). The cockpit's measured peer set (industry) also includes iRhythm (IRTC), Carl Zeiss Meditec (AFX.DE), Zhende Medical (603301.SS), iRay Technology (688301.SS), MGI Tech (688114.SS), TransMedics (TMDX).
Is Lepu Medical Technology (Beijing) expensive compared with its peers?
On forward p/e it trades at 24.4× against a peer median of 25.7×, 8th cheapest of 18 in its peer set. For today's price to make sense, revenue must grow about 9% a year for seven years (Req g). Recent delivered growth is -4%, so the hurdle is +13 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Lepu Medical Technology (Beijing) stock performed?
Over six months to 18 Nov 2026 the shares returned -12.8% against +3.2% for the median peer; over one year -31.3%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.